Compare SS&C Technologies Holdings Inc. Common Stock (SSNC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SS&C Technologies Holdings Inc. Common Stock vs Viatris Inc — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B), while Viatris Inc trades at $17.59 (market cap $19.81B). The key difference: SS&C Technologies Holdings Inc. Common Stock and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| SSNC | VTRS | |
|---|---|---|
Market Cap | $19.13B | $19.81B |
Volume | 1,333,448 | 7,547,542 |
Sector | Technology | Health |
52-Week High | $89.62 | $18.27 |
52-Week Low | $62.05 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $26.47B | $31.92B |
Dividend Yield | 1.47% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Viatris (VTRS) trades at $17.25, down 1.65% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue remains stable around $14.3B annually, though the company posted a net loss of $3.51B in 2025. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target, representing 28% upside potential.
The outlook suggests potential upside from current levels if earnings momentum continues, supported by strong cash flow generation and dividend payments. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the generic drug market. The stock appears reasonably valued with P/S of 1.36x, but the elevated P/E of 236x reflects current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
